Navas et al., 2017 - Google Patents
A clinically validated multiplex immunofluorescence assay for the quantitative assessment of changes in EMT phenotypes in FFPE tumor tissues in response to cancer …Navas et al., 2017
View PDF- Document ID
- 11654564141505263580
- Author
- Navas T
- Hollingshead M
- Borgel S
- Carter J
- Millione A
- Gouker B
- Butcher D
- Holbeck S
- Srivastava A
- Wilsker D
- Kinders R
- Bottaro D
- Kummar S
- Chen A
- Doroshow J
- Parchment R
- Publication year
- Publication venue
- Cancer Research
External Links
Snippet
Materials and Methods• The conversion of carcinoma cells from an epithelial to a mesenchymal phenotype (epithelial-mesenchymal transition, or EMT) is of considerable interest to clinicians due to the role of EMT in the promotion of tumor invasiveness …
- 206010028980 Neoplasm 0 title abstract description 57
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Farrand et al. | Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission | |
| JP3699399B2 (en) | Methods for determining response to cancer treatment | |
| Song et al. | Polyamine-targeting gefitinib prodrug and its near-infrared fluorescent theranostic derivative for monitoring drug delivery and lung cancer therapy | |
| JP2007526455A (en) | Compositions and methods for characterizing, controlling, diagnosing, and treating cancer | |
| Inamura et al. | Notch1 regulates invasion and metastasis of head and neck squamous cell carcinoma by inducing EMT through c-Myc | |
| Stacchiotti et al. | Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour | |
| EP1720611A2 (en) | Diagnostic marker for cancer | |
| Chen et al. | Protective autophagy attenuates soft substrate-induced apoptosis through ROS/JNK signaling pathway in breast cancer cells | |
| Koike et al. | YM155 reverses rapamycin resistance in renal cancer by decreasing survivin | |
| Zhang et al. | Isolation and characterization of cancer stem cells from cervical cancer HeLa cells | |
| Ra et al. | Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluorocoxib A | |
| Ataseven et al. | HER2/neu, topoisomerase 2a, estrogen and progesterone receptors: discordance between primary breast cancer and metastatic axillary lymph node in expression and amplification characteristics | |
| Toniti et al. | Immunohistochemical determination of estrogen and progesterone receptors in canine mammary tumors | |
| Garofano et al. | Prostate cancer cell-platelet bidirectional signaling promotes calcium mobilization, invasion and apoptotic resistance via distinct receptor-ligand pairs | |
| JP5413818B2 (en) | Protein quantification by fluorescence multiple staining | |
| Qu et al. | Over-expression of FRZB in gastric cancer cell suppresses proliferation and induces differentiation | |
| Navas et al. | A clinically validated multiplex immunofluorescence assay for the quantitative assessment of changes in EMT phenotypes in FFPE tumor tissues in response to cancer therapeutics | |
| Rana'a et al. | Prognostic associations of insulin-like growth factor-1 receptor in primary uveal melanoma | |
| EP3413045B1 (en) | Diagnosis marker for rare hematopoietic tumor, test method, therapeutic agent, and screening method | |
| Hanemann et al. | Histologic grading and nucleolar organizer regions in oral squamous cell carcinomas | |
| Min et al. | Muscular invasion by oral squamous cell carcinoma of the posterior mandibular alveolar ridge is associated with cervical lymph node metastasis | |
| Yoshida et al. | SMARCB1-deficient myoepithelial carcinoma of the lung: A case report | |
| Advani et al. | A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia | |
| Shelke et al. | Expression of yes-associated protein in oral squamous cell carcinoma | |
| US12013398B2 (en) | Compositions and methods for treatment of invasive cancers |